An observational study in ORL Cancer, sponsored by Institut Claudius Regaud. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Institut Claudius Regaud · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Single-centre prospective pilot study designed to demonstrate the acceptability of onco-sexology management for laryngectomy patients and their partners in order to improve their perception of their intimate life. This is a non-interventional study (category 3 Loi Jardé), which will not result in any change in patient management. All procedures will be carried out in accordance with standard practice.
Patients will be followed for 14 months.
Institut Claudius Regaud is the lead sponsor of 117 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with cancer (ORL) treated by laryngectomy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For patients:
For partners (if applicable) :
Exclusion Criteria:
For patients:
For partners (if applicable):
1. Patients deprived of their liberty or under legal protection (guardianship and tutorship, safeguard of justice).
Other: In this research, the procedure under study is represented:
* On the one hand, by carrying out sexology consultations which consist of individual interviews with a qualified sexologist nurse. * Secondly, questionnaires to assess quality of life and sexual function, to be completed by patients during standard follow-up consultations; and a questionnaire on satisfaction with sexological follow-up, to be completed by patients and their partners (if applicable) during the last standard follow-up consultation.
The primary endpoint is defined as the rate of patients meeting the acceptability criteria for onco-sexology management.
This rate corresponds to the ratio of the number of patients meeting the acceptability criteria to the total number of patients included. Acceptability is defined when the following two criteria are validated: * Completion of onco-sexology consultations 2 and 3 (at 3 and 12 months after cancer treatment) * Patient satisfaction ≥ 3 on a numerical scale from 1 to 5.
Time frame: 14 months for each patient
For the patients: Patients' sexual satisfaction will be assessed using the specific scale of the EORTC QLQSHQ-C22 questionnaire.
The score, which ranges from 0 to 100, is determined according to the algorithm published by the EORTC, based on answers to 8 questions. This is a self-administered questionnaire validated in French
Time frame: 14 months for each patient
For the patients: Quality of life will be assessed using the EORTC QLQ-C30 questionnaire and the disease-specific QLQ-H&N43 questionnaire.
These are self-administered questionnaires validated in French.
Time frame: 14 months for each patient
For the patients: The female sexual function (desire, arousal, pain, lubrication, satisfaction, orgasm).
The FSFI (Female Sexual Function Index) is a self-administered questionnaire validated in French. It comprises 19 items studying 6 dimensions of female sexual function (desire, arousal, pain, lubrication, satisfaction, orgasm) which make up an overall score of between 2 and 36.
Time frame: 14 months for each patient
For the patients: The ability to have sexual intercourse by considering several domains (erections, ejaculations, desire and satisfaction).
The MSHQ (Male Sexual Health Questionnaire) is a self-questionnaire validated in French which assesses the ability to have sexual intercourse by considering several domains (erections, ejaculations, desire and satisfaction).
Time frame: 14 months for each patient
For the patients: The impact of (pharyngo)laryngectomy totale on the couple's relationship.
It will be assessed using a descriptive analysis (marital status before and after cancer treatment, stability, strengthening or deterioration of the couple's relationship).
Time frame: 14 months for each patient
For the patients: Satisfaction or dissatisfaction with the onco-sexology consultation.
It will be assessed using a Likert scale. This type of scale was developed to measure attitudes and opinions (Rensis Likert 'A Technique for the Measurement of Attitudes', Archives of Psychology, vol.140, 1932, p. 1-55).
Time frame: 14 months for each patient
For the partner: - The rate of partners verifying the acceptability criteria for onco-sexology management is defined by the ratio of the number of partners verifying the acceptability criteria to the total number of partners included.
The definition of acceptability is the same as for the primary endpoint.
Time frame: 14 months for each partner
For the partner: The impact of the (pharyngo)laryngectomy totale on the couple's relationship will be assessed using a descriptive analysis (stability, reinforcement or deterioration of the couple's life).
Time frame: 14 months for each partner
For the partner: Satisfaction or dissatisfaction with the onco-sexology consultation will be assessed using a Likert scale.
Time frame: 14 months for each partner
Started Jul 2024 (actual). Primary completion is estimated for Sep 2030, 74 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion Mar 2028 → Sep 2030 and completion Mar 2028 → Sep 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.